Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period. After the optimal administered activity and imaging time window are selected in Phase 2, Phase 3 will enroll participants with recently diagnosed PCa who are at least high risk or have suspected metastatic disease and are eligible for radical prostatectomy with pelvic lymph node dissection (RP+PLND). Safety assessments throughout the study will include monitoring of adverse events, vital signs, ECGs, and clinical laboratory parameters. Participants will be enrolled sequentially in a nonrandomized manner, with competitive enrollment across study sites.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna w wieku co najmniej 18 lat
- •Potwierdzony histologicznie rak prostaty (adenokarcynoma) zaawansowany lub podejrzany o przerzuty
- •Dobra ogólna kondycja zdrowotna (ECOG 0-2)
- •Prawidłowa funkcja wątroby, nerek i szpiku kostnego
- •Gotowość do zastosowania antykoncepcji przez 7 dni po podaniu leku badawczego
- •Chętny do zabrania antylek jeśli jest klaustrofobiczny
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 21, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
BAMF Health
Grand Rapids, United States
Trial contact
Eryn Bagley
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.